Core Viewpoint - Guerbet reported a 6.5% decline in sales for the full year 2025, totaling €786.4 million, with a more moderate decline of 3.8% at constant exchange rates (CER) [3][10]. Financial Performance - The decline in sales was primarily attributed to a 5.4% drop in the first half of the year, followed by a 2.6% increase in Q3, and a 5.6% decline in Q4, influenced by issues at the Raleigh industrial site in the U.S. [4][10]. - Revenue breakdown for Q4 2025 showed a total of €200.0 million, down 9.4% compared to Q4 2024, with a decline of 5.6% at CER [5][11]. Geographical Breakdown - In EMEA, full-year sales were €343.7 million, down 2.5% at CER, with a notable growth of 7.6% excluding France [7]. - The Americas reported revenue of €233.0 million, a decrease of 3.8% at CER, with a significant contraction of 8.6% in Q4 due to production delays at the Raleigh site [8]. - In Asia, sales totaled €207.9 million, down 4.8% at CER, impacted by the loss of a customer in Vietnam [9]. Segment Performance - Diagnostic Imaging revenue for the year was €678.2 million, a decrease of 5.3% at CER, with a 9.1% decline in Q4 [11]. - Interventional Imaging saw revenue increase to €106.3 million, up 9.7% at CER, driven by strong demand for Lipiodol in vascular embolization [12]. Future Outlook - The company confirmed its forecast for a restated EBITDA margin between 10.5% and 12% for 2025 and revised its Free cash flow target to be positive [13]. - The ongoing situation at the Raleigh site is expected to continue affecting revenue, profitability, and cash generation in 2026 [15][16].

Core Viewpoint - Guerbet is experiencing a return to growth in Q3 2025, confirming all financial targets for the year, with expectations of continued improvement in Q4 2025 [1][12][13]. Financial Performance - Group sales for the first nine months of 2025 totaled €586.5 million, a decrease of 5.5% compared to the previous year. At constant exchange rates, sales fell by 3.1% [3][9]. - The third quarter showed a sequential improvement with sales growth of 2.6% at constant exchange rates and on a like-for-like basis, following declines of 7.1% and 3.9% in the first and second quarters, respectively [4][9]. - Revenue breakdown for Q3 2025: - EMEA: €86.2 million, up 10.2% at constant exchange rates - Americas: €58.8 million, down 10.7% at constant exchange rates - Asia: €53.7 million, down 4.4% at constant exchange rates [5][6][7]. Regional Performance - EMEA region sales for the first nine months were €255.8 million, down 2.3% at constant exchange rates, with a notable recovery in Q3 [5]. - Americas region revenue was €176.5 million, down 2.2% at constant exchange rates, with a significant decline in Q3 attributed to a weaker performance in Latin America [6]. - Asia region revenue totaled €152.4 million, down 4.3% at constant exchange rates, but showed positive growth of 1.5% in Q3 driven by strong sales in Japan [7]. Product Segment Performance - Diagnostic Imaging revenue for the first nine months was €508.0 million, down 4.0% at constant exchange rates, with a return to growth of 1.7% in Q3 [10]. - Interventional Imaging sales reached €76.7 million, reflecting a 6.0% increase at constant exchange rates, with Q3 growth of 8.8% driven by strong performance of Lipiodol [11][16]. Future Outlook - Guerbet anticipates a slight decline in revenue of around -1% for 2025, with an EBITDA margin expected between 12-13%. Free cash flow is projected to be slightly negative for the year [13]. - The company expects continued growth in Q4 2025, supported by the ramp-up of Elucirem and positive momentum in indirect sales across various regions [12][13].